...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
【24h】

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

机译：非典型抗精神病药治疗患者血清瘦素和甘油三酯水平。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Weight gain is a common adverse effect associated with the use of most antipsychotic drugs. Leptin has been reported to be associated with antipsychotic-induced weight gain. Previous studies have demonstrated a relationship between the atypical antipsychotics clozapine and olanzapine and serum leptin levels. We planned to comparatively investigate the effects of the atypical antipsychotics quetiapine, olanzapine, risperidone, and clozapine on leptin and triglyceride levels and weight gain. METHOD: The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment. The patients were evaluated at baseline and at the sixth week according to the Positive and Negative Syndrome Scale (PANSS), body mass index (BMI), weight, and fasting serum leptin and triglyceride levels. Data were gathered in 2001 and 2002. RESULTS: Olanzapine and clozapine caused a marked increase in weight and serum triglyceride and leptin levels, though increases in these variables were modest in the patients receiving quetiapine and minimal in those receiving risperidone. There were positive correlations between serum leptin levels and BMI and triglyceride levels. Clinical efficacy, as indicated by decrease in total PANSS scores, was associated with leptin levels in all atypical antipsychotic groups. CONCLUSION: Our results suggest that leptin may be associated with olanzapine- and clozapine-induced weight gain and that quetiapine appears to have modest influence and risperidone appears to have minimal influence on leptin and triglyceride levels and weight gain compared with olanzapine and clozapine.
机译：背景：体重增加是与使用大多数抗精神病药物相关的常见不良影响。据报道，瘦素与抗精神病药诱导的体重增加有关。以前的研究表明，非典型抗精神病药氯氮平和奥氮翼和血清瘦素水平之间的关系。我们计划相对调查非典型抗精神病药喹啉喹啉，奥氮萘葡萄球菌，酮酮和氯氮平对瘦素和甘油三酯水平和体重增加的影响。方法：研究人群包含56例DSM-IV精神分裂症患者，被分为4组：喹诗（n = 14），奥氮藻（n = 14），氯酮（n = 14）或氯氮平（n = 14）单一疗法，以及11例患者接受没有精神医学治疗的对照组。根据正极和阴性综合征尺度（平底锅），体重指数（BMI），重量和空腹血清瘦素和甘油三酯水平，在基线和第六周评估患者。结果于2001年和2002年收集。结果：奥氮平和氯氮平导致重量和血清甘油三酯和瘦素水平的显着增加，尽管这些变量的增加是在接受喹硫酮的患者中接受喹诗和最小的患者。血清瘦素水平与BMI和甘油三酯水平之间存在正相关性。临床疗效，如总平底锅得分的降低所表明，与所有非典型抗精神病药组中的瘦素水平有关。结论：我们的研究结果表明，瘦素可能与奥氮平和氯氮平诱导的体重增加有关，并且喹诗氏素似乎具有适度的影响力，并且利比酮似乎对瘦蛋白和甘油三酯水平的影响最小，而且与奥氮平和氯氮平相比的体重增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号